![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 24, 2020 9:53:48 AM
The most positive development presented at the conference may be that ARTH has discovered the fact that 3-D Matrix Medical Technology Ltd (acompany with a very similar technology to ARTH) has developed a business in Europe for its product (PuraStat) as a hemostat in GI endoscopy procedures. (Check out the website.) 3-D Matrix has capitalized on the fact that the procedure is not considered internal surgery from a regulatory perspective and the device is regulated as Class II. ARTH's blue AC5 seems to be targeted at this indication.
The technology seems to have potential. It's up to ARTH management to find a way to use it.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM